NCT06796907

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 392 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable GSK5733584 is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

Conditions

• Tumours, Gynecological

Interventions

Type	Name	Description
DRUG	GSK5733584	GSK5733584 will be administered intravenously (IV).
DRUG	Dostarlimab	Dostarlimab will be administered IV.
DRUG	Bevacizumab	Bevacizumab will be administered IV.
DRUG	Anticancer therapy 3	Anticancer therapy 3 will be administered IV.
DRUG	Anticancer therapy 4	Anticancer therapy 4 will be administered IV.

Timeline

• Start date: 2025-03-04
• Primary completion: 2027-12-17
• Completion: 2028-04-05
• First posted: 2025-01-28
• Last updated: 2025-10-14

Locations

56 sites across 20 countries: Argentina, Australia, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Japan, Netherlands, Norway, Panama, Poland, South Korea, Spain, Sweden, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study